Search
Bromotheophylline
go.drugbank.com/drugs/DB14018Approved[A33018] Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. … From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome.
Futibatinib
go.drugbank.com/drugs/DB15149ApprovedInvestigationalFutibatinib is an inhibitor of Fibroblast Growth Factor receptor (FGFR), which comprises a group of receptor tyrosine kinases that play a key role in cell proliferation, differentiation, migration, and … FGFR was investigated in oncology as a therapeutic target, as FGFR genomic aberrations and dysregulated FGFR signalling pathways are observed in some cancers such as cholangiocarcinoma and urothelial malignancies
Categories: Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitorsDarolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalDarolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists.
Categories: Androgen Receptor InhibitorsPixantrone
go.drugbank.com/drugs/DB06193ApprovedWithdrawnIt also inhibits doxorubicinol formation in human myocardium. [3] As a result, it is believed to be less cardiotoxic while still exerting efficacy. … Pixantrone dimaleate, administered intravenously, was designed by Cell Therapeutics Incorporated as an alternative second line therapy in refractory or relapsed NHL.
Thiohexam
go.drugbank.com/drugs/DB14200ApprovedThiohexam is a rubber cure accelerator. It is also a known allergen and dermatological sensitizer. Sensitivity to Thiohexam may be identified with a clinical patch test.
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational_PIK3CA_ is one of the most frequently mutated oncogenes, with the resulting mutated p110α protein it encodes playing a central role in tumor cell proliferation. … Inavolisib is an inhibitor of PI3Kα that was approved by the FDA in October 2024 for the treatment of certain patients with advanced breast cancers.
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawnFluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358,F4361,F4364][FDA Label]. … These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label].
Categories: Corticosteroid Hormone Receptor AgonistsEgg phospholipids
go.drugbank.com/drugs/DB14233ApprovedWithdrawnEgg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition. … Egg phospholipids are primarily a mixture of naturally occurring phospholipids which are isolated from the egg yolk.
Patisiran
go.drugbank.com/drugs/DB14582ApprovedIt is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … Patisiran is a first in class short interfering RNA for the treatment of patients with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis [L4220].
Categories: Compounds used in a research, industrial, or household settingIsocarboxazid
go.drugbank.com/drugs/DB01247Approved[T115] It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959. … It is a monoamine oxidase inhibitor.[A31930] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders.
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates